Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when stem cell transplant is unsuitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 3843
Provisional Schedule
- Draft guidance:
- 09 January 2026 - 30 January 2026
- Committee meeting: 2:
- 12 March 2026
- Expected publication:
- 13 May 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- Janssen (daratumumab)
- Others
- Department of Health and Social Care
- NHS England
- Heath Technology Wales
- Patient carer groups
- Blood Cancer UK
- Myeloma UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK Myeloma Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Advanz Pharma (lenalidomide)- No CAU- Not Participating
- Amarox (lenalidomide) - No CAU- Not Participating
- Aspire Pharma (bortezomib) - No CAU- Not Participating
- Aurobindo Pharma (bortezomib) - No CAU- Not Participating
- Biocon Pharma (lenalidomide) - No CAU- Not Participating
- Biotech Pharma (bortezomib) - No CAU- Not Participating
- Bristol Myers Squibb (lenalidomide)- CAU received- participating
- Dr Reddy’s Laboratories (bortezomib)- No CAU- Not Participating
- Grindeks Kalceks (lenalidomide)- No CAU- Not Participating
- Mylan (lenalidomide) - No CAU- Not Participating
- MSN laboratories Europe (bortezomib) - No CAU- Not Participating
- Pfizer (bortezomib) - No CAU- Not Participating
- Piramal Critical Care (lenalidomide) - No CAU- Not Participating
- Ranbaxy (bortezomib, lenalidomide) - No CAU- Not Participating
- Sandoz (bortezomib, lenalidomide) - No CAU- Not Participating
- Sanofi (isatuximab) No CAU- Not Participating
- Teva UK (lenalidomide)- No CAU- Not Participating
- Thornton & Ross (bortezomib, lenalidomide) - No CAU- Not Participating
- Tillomed Laboratories (bortezomib) - No CAU- Not Participating
- Zentiva (bortezomib)- No CAU- Not Participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 December 2025 | Committee meeting: 1 |
| 13 May 2025 | Invitation to participate |
| 17 March 2025 - 14 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3843 |
| 17 March 2025 | In progress. Scoping commencing |
| 04 November 2024 | Please note that following on from a request received from the company, the appraisal has been scheduled back into the work programme and it is now anticipated to begin in early mid-May 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-July 2025. |
| 19 July 2023 | Suspended. Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 16 June 2021 | Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual